103577-66-8

Basic information

• Product Name: 2-Hydroxymethyl-3-methyl-4-(2,2,2-trifluoroethoxy)pyridine hydrochloride
• Synonyms: 2-trifluoro-ethoxy)-pyridin-2-yl]-Methanol;Lansoprazole hydroxy coMpound;2-PyridineMethanol,3-Methyl-4-(2,2,2-trifluoroethoxy)-;2-HYDROXYMETHYL-3-METHYL-4-(2,2,2-THIFLUOROETHOXY)PYRIDINE;2-HYDROXYMETHYL-3-METHYL-4-(2,2,2-TRIFLUOROETHOXY) PYRIDINE;[3-METHYL-4-(2,2,2-TRIFLUORO-ETHOXY)-PYRIDIN-2-YL]-METHANOL;[3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL]METHONOL;3-Methyl-4-(2,2,2-Trifluoroethoxy)-2-Pyridinemethanol
• CAS NO: 103577-66-8
• Molecular Formula: C₉H₁₀F₃NO₂
• Molecular Weight: 257.64
• EINECS: 1308068-626-2
• Mol File: 103577-66-8.mol
• Article Data: 5

Chemical Properties

• Melting Point: 93-94 °C(Solv: isopropyl ether (108-20-3); hexane (110-54-3))
• Boiling Point: 273.6 °C at 760 mmHg
• Flash Point: 119.3 °C
• Appearance: /
• Density: 1.303 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 13.17±0.10(Predicted)
• CAS DataBase Reference: 2-Hydroxymethyl-3-methyl-4-(2,2,2-trifluoroethoxy)pyridine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Hydroxymethyl-3-methyl-4-(2,2,2-trifluoroethoxy)pyridine hydrochloride(103577-66-8)
• EPA Substance Registry System: 2-Hydroxymethyl-3-methyl-4-(2,2,2-trifluoroethoxy)pyridine hydrochloride(103577-66-8)

Safety Data

• Hazardous Substances Data: 103577-66-8(Hazardous Substances Data)

Usage

Chemical Properties

Brown Solid

Uses

Intermediate in the preparation of Lansoprazole (L175000) impurity.

InChI:InChI=1/C9H10F3NO2.ClH/c1-6-7(4-14)13-3-2-8(6)15-5-9(10,11)12;/h2-3,14H,4-5H2,1H3;1H

Upstream product

• 583-61-9 2,3-Lutidine 
• 22710-07-2 2,3-dimethylpyridine 1-oxide 
• 37699-43-7 2,3-dimethyl-4-nitropyridine N-oxide 
• 103577-61-3 2,3-dimethyl-4-(2,2,2-trifluoroethoxy)-pyridine N-oxide 
• 112525-75-4 2-acetoxymethyl-3-methyl-4-(2,2,2-trifluoroethoxy)pyridine 

Downstream Products

• 128430-66-0 2-(chloromethyl)-3-methyl-4-(2,2,2-trifluoroethoxy)pyridine 
• 138530-94-6 (R)-lansoprazole 
• 103577-40-8 lansoprazole sulfide 
• 103577-45-3 lansoprasole 

Relevant articles and documents

Design and synthesis of N-Aryl isothioureas as a novel class of gastric H+/K+-ATPase inhibitors

To find new H+/K+-ATPase inhibitors for the treatment of peptic ulcer disease, a series of novel N-aryl isothiourea derivatives were synthesized and their structures were identified by 1H NMR and GC-MS. The effects of these compounds on inhibiting gastric acid secretion were evaluated by the guinea pig stomach mucous membrane study with pantoprazole magnesium as a positive control. The results showed that, of the 37 N-aryl isothiourea compounds synthesized, 20 compounds have comparable or stronger gastric acid inhibitory activities than that of pantoprazole magnesium. The quantitative structure-activity relationships (QSARs) of the N-aryl isothiourea compounds were also studied by comparative molecular field analysis (CoMFA) computation, and the model structure that was supposed to give more powerful bioactivities was finally predicted. A series of novel N-aryl isothiourea derivatives were synthesized and evaluated for their effects of inhibiting gastric acid secretion using the guinea pig stomach mucous membrane study with pantoprazole magnesium as a positive control. Compounds 2c, 2e, and 2k have higher bioactivity. The quantitative structure-activity relationships also defined these structural requirements.

Crystals of benzimidazole derivatives and their production

A substantially solvent-free and stable crystal of the compound of the formula: STR1 wherein the ring A may optionally be substituted, R1 represents hydrogen or an N-protecting group, each of R2, R3 and R4 (1) a hydrogen atom, (2) an alkyl group which may optionally be substituted with halogen atom(s) or (3) an alkoxy group which may optionally be substituted with halogen atom(s) or alkoxy; or its salt, is produced by subjecting a solvate of the compound (I) or its salt to de-solvent treatment, in an industrially advantageous method.

Synthesis of 2-[[(4-fluoroalkoxy-2-pyridyl)methyl]sulfinyl]-1H-benzimidazoles as antiulcer agents

-